Drug approvals bounce back as R&D labs churn out new winners

LONDON, May 25 (Reuters) - The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.